[go: up one dir, main page]

MX2023011556A - Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4. - Google Patents

Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4.

Info

Publication number
MX2023011556A
MX2023011556A MX2023011556A MX2023011556A MX2023011556A MX 2023011556 A MX2023011556 A MX 2023011556A MX 2023011556 A MX2023011556 A MX 2023011556A MX 2023011556 A MX2023011556 A MX 2023011556A MX 2023011556 A MX2023011556 A MX 2023011556A
Authority
MX
Mexico
Prior art keywords
s1pr4
s1pr1
preventing
pharmaceutical composition
alopecia areata
Prior art date
Application number
MX2023011556A
Other languages
English (en)
Inventor
Eun Jeong Kim
Bongyong Lee
Yanghae Park
Original Assignee
Nextgen Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextgen Bioscience Co Ltd filed Critical Nextgen Bioscience Co Ltd
Priority claimed from PCT/KR2023/012725 external-priority patent/WO2024085417A1/ko
Publication of MX2023011556A publication Critical patent/MX2023011556A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para prevenir o tratar la alopecia areata que actúa como un antagonista funcional para los subtipos S1PR1 y S1PR4 del receptor S1P, y más particularmente, se refiere a una composición farmacéutica que contiene como un ingrediente activo un compuesto esfingolípido que actúa como antagonista funcional de S1PR1 y S1PR4, no causa efectos secundarios cardiovasculares, y es efectivo para prevenir o tratar la alopecia areata.
MX2023011556A 2022-10-21 2023-08-28 Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4. MX2023011556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263418071P 2022-10-21 2022-10-21
PCT/KR2023/012725 WO2024085417A1 (ko) 2022-10-21 2023-08-28 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2023011556A true MX2023011556A (es) 2024-07-19

Family

ID=89076468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011556A MX2023011556A (es) 2022-10-21 2023-08-28 Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4.

Country Status (7)

Country Link
US (1) US11957665B1 (es)
EP (1) EP4606373A1 (es)
JP (1) JP7607376B2 (es)
CN (1) CN118234492A (es)
AU (1) AU2023248144B2 (es)
CA (1) CA3213748C (es)
MX (1) MX2023011556A (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
DE602004027932D1 (de) 2003-09-22 2010-08-12 S Bio Pte Ltd Benzimidazolderivate: herstellung und pharmazeutische anwendungen
BRPI0810123A2 (pt) 2007-04-23 2014-10-29 Novartis Ag Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1p
ES2652451T3 (es) * 2013-04-04 2018-02-02 Phytos Co., Ltd. Nuevo derivado de la fitoesfingosina-1-fosfato, método de preparación del mismo, y composición para prevenir y tratar la pérdida del cabello o para estimular el crecimiento del cabello que comprende el mismo
KR101830244B1 (ko) * 2016-01-20 2018-02-21 서울대학교 산학협력단 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
AU2021205465A1 (en) 2020-01-06 2022-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR102540720B1 (ko) * 2020-02-18 2023-06-08 재단법인 아산사회복지재단 천식 또는 기관지염 예방 또는 치료용 약학적 조성물
KR102533409B1 (ko) 2021-11-04 2023-05-26 주식회사 넥스트젠바이오사이언스 2-아미노-2-(2-(1-데실-1h-1,2,3-트라이아졸-4-일)에틸)프로판-1,3-다이올의 신규염 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
AU2023248144A1 (en) 2024-05-09
US11957665B1 (en) 2024-04-16
JP7607376B2 (ja) 2024-12-27
US20240148698A1 (en) 2024-05-09
EP4606373A1 (en) 2025-08-27
AU2023248144B2 (en) 2024-05-23
JP2024539788A (ja) 2024-10-31
CA3213748A1 (en) 2023-12-08
CN118234492A (zh) 2024-06-21
CA3213748C (en) 2025-02-11

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2007015863A (es) Inhibidores de esfingosina cinasa.
MA37834A1 (fr) Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
PH12021552555A1 (en) Dihydroorotate dehydrogenase inhibitors
TW200744586A (en) Therapeutic compounds
MA54458B1 (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
PH12021552201A1 (en) Benzodiazepine derivatives as rsv inhibitors
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2024010863A (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2).
PH12021553202A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide
MA39983B1 (fr) Dérivés de carboxamide
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
MX2023011556A (es) Composición farmacéutica para prevenir o tratar la alopecia areata actuando como un antagonista funcional de s1pr1 y s1pr4.
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
BR112021025288A2 (pt) Composição fungicida sinergística